TX-H3-DYNAMICS
4.1.2023 10:31:40 CET | Business Wire | Press release
H3 Dynamics is announcing the global launch of H2FIELD-1, a new hydrogen station capable of producing hydrogen in the field for unmanned aerial vehicles of all shapes, sizes and configurations.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230104005066/en/
H3 Dynamics announces H2FIELD mobile hydrogen station for hydrogen drones and UAVs of all shapes and sizes, from hydrogen production to automatic refilling in the field. (Photo: Business Wire)
Now hydrogen-powered airships, multi-rotors, vertical take-off and landing UAS and various fixed wing systems will be able to benefit from 24/7 hydrogen supply anywhere, anytime.
H2FIELD’s rugged IP-65 trailer-based solution brings hydrogen production to different drone operation locations. It can also be dismounted as a permanent installation and connect to solar panel arrays. H3 Dynamics can supply various configurations, with slow or fast charge options down to minutes per fill - depending on client requirements. H3 Dynamics’ system is extremely compact and can produce hydrogen on site - not just dispense it from other storage forms.
For hydrogen drone operators, H2FIELD-1 solves fundamental hydrogen accessibility in remote areas, unlocking a major logistical barrier for a growing base of hydrogen drone operators in industrial, defense, or even academic sectors. The only feedstock input is water.
H3 Dynamics has been working on a first transatlantic hydrogen-electric flight using liquid hydrogen storage systems currently being tested in France with ISAE-SUPAERO in Toulouse. Last week H3 Dynamics announced its hydrogen propulsion partnership with French airship maker HyLight, and the week prior with Australian VTOL UAV producer Carbonix whose airframes are made by Quickstep - Australia’s leading aerospace composites producer.
2023 will see more of these announcements as H3 Dynamics continues to transition battery-UAS manufacturers to hydrogen technologies. Compared to batteries, hydrogen electric systems increase battery-drone flight durations by several orders of magnitude, opening to many new possibilities in a market that is expected to grow five-fold to $100B by 2030.
H2FIELD-1 marks the start of H3 Dynamics’ foray into hydrogen infrastructure solutions for small, unmanned and increasingly large aircraft, from airfields to airports - with increasingly large output power and hydrogen storage capabilities.
“We are the evolutionary starting point to increasingly large hydrogen powered flight platforms, where testing, certification and regulatory approval challenges vary based on aircraft weight. We want to mature hydrogen technology in today’s existing uncrewed aviation market - and that includes working out hydrogen logistics and refueling systems,” says Taras Wankewycz, CEO and co-Founder at H3 Dynamics.
About H3 Dynamics www.h3dynamics.com
H3 Dynamics is on a mission to decarbonize aviation. While the commercial opportunities around passenger-scale hydrogen aviation propulsion will take many more years to mature, the company is following a “start small” product and services roadmap that solves safety, technical, regulatory challenges by adding scale, weight and complexity over time. The company employs 94 team members from its 3 regional headquarters in Toulouse, Austin and Singapore. H3 Dynamics is a member of the Alliance for Zero Emission Aviation under the European Commission, Sustainable Aero Lab, the Lufthansa Cleantech Hub, the Paris Advanced Air Mobility Alliance, and Aerospace Valley in Toulouse.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230104005066/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AI Meets Traditional Culture: Huangshan Captures Widespread Attention at ITB Berlin7.3.2026 10:22:00 CET | Press release
Huangshan, one of China’s most iconic scenic destinations, drew significant attention at this year’s ITB by presenting a compelling fusion of traditional Chinese culture and cutting-edge artificial intelligence under the slogan “The world of Huangshan is for the world.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260307909978/en/ International visitor admires Huangshan cultural and creative exhibits at the Huangshan stand during ITB Berlin. Located in eastern China’s Anhui Province, Huangshan is famed for its “Five Natural Wonders” — fantastic pines, grotesque rocks, sea of clouds, hot spring and winter snow. The mountain is widely regarded as one of China’s greatest mountain landscapes. It is also a rare natural heritage site that simultaneously holds multiple international designations, including UNESCO World Cultural and Natural Heritage status, a UNESCO Global Geopark and a World Biosphere Reserve. At ITB, the Huangsh
Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 22:42:00 CET | Press release
- Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult patients with advanced SCAC in Europe- The EC approval is based on results of the POD1UM-303 study which showed that adult patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment compared to chemotherapy alone.1 Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meur
Dfns Launches Payouts6.3.2026 21:27:00 CET | Press release
Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i
Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 20:23:00 CET | Press release
Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up
Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 18:30:00 CET | Press release
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom